SLU-PP-332 – Research-Grade ERR Agonist (500 mcg Capsules)

Supplied by: Combat Research
CAS Number: 303760-60-3
Other Names: SLUPP332, SLU PP-332, pan-ERR agonist, CHEMBL4208749
Molecular Formula: C₁₈H₁₄N₂O₂
Molecular Weight: 290.32 g/mol
Form: Dry-Fill Capsules
Concentration: 500 mcg per capsule
Packaging Options: 50 capsule units
Intended Use: Laboratory and Scientific Research Only

🔬 Scientific Overview

SLU-PP-332 is a novel pan-estrogen-related receptor (ERR) agonist, studied for its ability to activate ERRα, ERRβ, and ERRγ, key regulators of mitochondrial energy metabolism and fatty acid oxidation. Offered by Combat Research, our 500 mcg capsule format is ideal for precise, pre-measured dosing in controlled in vivo and ex vivo research models.

SLU-PP-332 has been shown in preclinical models to:

• Mimic exercise by promoting oxidative muscle metabolism

• Enhance mitochondrial biogenesis and energy expenditure

• Reduce body weight and adipose tissue in high-fat diet models

• Improve glucose tolerance and insulin sensitivity

• Operate independently of caloric restriction or stimulants

📚 Published Research & References

• Alexandre K. et al. (2023). A pan-ERR agonist that mimics exercise and reduces obesity in mice.
  Nature Communications. https://doi.org/10.1038/s41467-020-19776-7

• PubMed Index of SLU-PP-332 Research:
  https://pubmed.ncbi.nlm.nih.gov/37739806

• Supporting Mitochondrial Biology Studies:
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10801787

⚠️ NOT FOR HUMAN USE – FOR RESEARCH ONLY

SLU-PP-332 is supplied by Combat Research solely for scientific research and development.
This compound is not approved by the FDA for medical, nutritional, or diagnostic use.

Not for human or veterinary consumption. Do not ingest, inject, inhale, or apply topically.
This product may only be handled by qualified personnel in controlled laboratory settings.

Certificate of Analysis (COA) and Safety Data Sheet (SDS) available upon request. Each unit is sealed, lot-traceable, and batch verified.

🔬 Key Studies on Cardarine (GW‑501516)

1. Phase II Dyslipidemia Trial in Humans

Title: GW501516 in subjects with low HDL-cholesterol (Phase II, GlaxoSmithKline)

• A multicenter, randomized, double‑blind, placebo‑controlled dose-range study (12 weeks) investigating 2.5, 5.0, and 10 mg daily in adults with HDL‑C ≤45 mg/dL.

• Results: up to 17% increase in HDL‑C, 7–15% reduction in LDL and triglycerides, improved lipoprotein subclass profiles (e.g., fewer small LDL, increased HDL particles) Clinical Trials Register+10BEHEMOTH LABZ+10Therapeutic Goods Administration (TGA)+10Wikipedia+7PubMed+7ClinConnect+7.

2. Exploratory Lipoprotein Particle Substudy

Title: Lipoprotein subclass profiling with GW501516

• A small exploratory arm (n≈37) escalated from 5 mg to 10 mg daily.

• Findings: significant reductions in very‑LDL (~19%), intermediate LDL (~52%), small LDL (~14%), and increases in HDL particle number (~10%) PubMed.

3. Phase I / Phase II Early Safety Trials

Title: Safety and tolerability of daily GW501516 dosing in healthy volunteers

• Phase I/II trials (2000–2007) assessed 2.5–10 mg once daily for up to 12 weeks in sedentary adults.

• No significant adverse impact on liver or muscle enzymes. Triglycerides improved, and HDL rose modestly, with no acute safety signals noted Reddit.

4. Preclinical Animal Studies & Mechanistic Research

Title: Effects of GW501516 on endurance, metabolism, and cancer risk

• In mice and obese non‑human primates, Cardarine significantly enhanced endurance performance, fatty acid oxidation, and HDL elevation; but long-term studies revealed carcinogenicity in multiple organs, prompting drug development termination in 2007 Reddit+10Wikipedia+10biolongevitysupplements.com+10.

• Animal models established changes in gene expression associated with mitochondrial biogenesis, anti-inflammatory cytokines, and energy metabolism via PPARδ activation biolongevitysupplements.com.

⚠️ Research & Medical Context

• Originally developed for treating metabolic syndrome, obesity, dyslipidemia, and cardiovascular conditions—clinical development reached Phase II but was terminated due to long-term carcinogenicity in animals Clinical Trials RegisterPubMedHealth+1Reddit+1Wikipedia+1PubMed+1CDEK+1MedPath+1PubMed+7The Conversation+7BEHEMOTH LABZ+7BEHEMOTH LABZ+3The New Yorker+3Therapeutic Goods Administration (TGA)+3.

• Mechanism: Selective PPARδ agonist that enhances fatty acid oxidation, HDL production, and mitochondrial function via transcriptional activation in skeletal muscle and liver tissues Wikipedia+10Reddit+10biolongevitysupplements.com+10.

• Safety concerns: Chronic rodent exposure at high doses caused tumors in multiple tissues, including liver, bladder, stomach; human trials showed no acute signals, but were short-term and did not assess carcinogenicity risks WikipediaThe Conversationbiolongevitysupplements.com.

• Regulatory status: Not FDA approved. Added to WADA’s prohibited list in 2009 due to misuse in sports and health risks Wikipedia+1biolongevitysupplements.com+1.